A Phase 2 interventional study of GZ/SAR402671 in Fabry Disease, sponsored by Genzyme, a Sanofi Company. Completed at 7 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-23.
Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Fabry Disease by Sanofi — 1 open to participants now, 3 under way, 2 of them phase 3. Fabry Disease · Sanofi.
Among the 23 studies in Fabry Disease by Sanofi, this one is the 14th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2015, is one of 5 in phase 2, and was the 16th registered.
244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
Browse Fabry Disease studies →1 of the 23 studies in Fabry Disease by Sanofi is open now, in 12 countries. Recruiting first, the newest first:
Genzyme, a Sanofi Company · Sites in United States, Argentina, Australia and 41 more countries
By country, each count listing its studies:
Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2015.
This study's enrollment of 8 is below the median of 22 across 108 interventional studies indexed under Fabry Disease.
Median enrollment 20 across the 19 interventional studies, 242 across the 4 observational. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Genzyme, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Genzyme, a Sanofi Company is the lead sponsor of 308 studies on the registry; 5 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 19 (76%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Fabry Disease by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To assess the long-term safety of GZ/SAR402671 in adult male participants with Fabry disease who previously completed study ACT13739 (NCT02489344).
Secondary Objective:
To assess the long-term effect of GZ/SAR402671 on pharmacodynamic and exploratory efficacy endpoints in adult male participants with Fabry disease who previously completed study ACT13739.
The total duration of this extension study (LTS14116) was up to 31 months (30 months of treatment and one month post-treatment follow-up).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria :
-Participants, in the opinion of the Investigator, unable to adhere to the requirements of the study.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received GZ/SAR402671 15 milligrams (mg) once daily orally for 30 months in this extension study (LTS14116).
Drug: GZ/SAR402671
Drug page: Venglustat
Pharmaceutical form:capsule Route of administration: oral
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened during TEAE period (period from the first administration of study drug in ACT13739 through the last administration of the study drug in the combined ACT13739/LTS14116 treatment period plus 1 month or end of study participation for participant, whichever occurred first). For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters
Criteria for potentially clinically significant abnormalities: * Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L); greater than or equal to (\>=)185 g/L; decreased from baseline (DFB) \>=20 g/L * Hematocrit: \<=0.37 volume/volume (v/v); \>=0.55 v/v * Erythrocytes: \>=6 Tera/L * Platelets: lesser than (\<) 100 Giga/L; \>=700 Giga/L * Leukocytes: \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); * Lymphocytes: greater than (\>) 4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L) For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes
Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 millimoles (mmol)/L; \>=160 mmol/L * Potassium: \<3 mmol/L; \>=5.5 mmol/L * Chloride: \<80 mmol/L; \>115 mmol/L.
Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters
Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>3 ULN; \>5 ULN; \>10 ULN and \>20 ULN * Aspartate aminotransferase (AST): \>3 ULN; \>5 ULN; \>10 ULN and \>20 ULN * Alkaline phosphatase: \>1.5 ULN * Bilirubin: \>1.5 ULN; \>2 ULN.
Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters
Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \< lower limits of normal (LLN); \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]) * Lipase: \>= 3 ULN * C Reactive Protein (CRP): \> 2 ULN or \> 10 milligrams (mg)/L (if ULN not provided).
Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters
Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromoles per liter (mcmol/L) (Adults); \>=30% change from baseline; \>= 100% change from baseline * Blood urea nitrogen: \>=17 mmol/L * Urate: \<120 mcmol/L; \>408 mcmol/L For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Urinalysis
Criteria with potentially clinically significant urine abnormalities: pH: \<= 4.6; pH: \>= 8.0
Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities
Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure (SBP) supine: \<=95 millimeters of mercury (mmHg) and DFB \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg * Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg * Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm * Weight: \>=5% DFB; \>=5% IFB For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
Criteria for potentially clinically significant ECG abnormalities: * ECG mean HR: \<30 bpm; \<30 bpm and DFB \>=20 bpm; \<40 bpm; \<40 bpm and DFB \>=20 bpm; \<50 bpm; \<50 bpm and DFB \>=20 bpm; \>90 bpm; \<90 bpm and DFB \>=20 bpm; \>100 bpm; \<100 bpm and DFB \>=20 bpm; \>120 bpm; \<120 bpm and DFB \>=20 bpm * PR Interval: \>200 milliseconds (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25% * QRS duration: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25% * QTc Bazett (QTcB) interval: \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms, IFB \>60 ms * QTc Fridericia (QTc F): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms * QT Interval: \>500 ms For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Change From Baseline in Plasma Globotriaosylceramide (GL-3) Concentration at Weeks 26, 52, 104, and 156
Change from baseline in plasma GL-3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GL-3 in plasma was determined using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Change From Baseline in Plasma Lyso Globotriaosylceramide (Lyso GL-3) Concentration at Weeks 26, 52, 104, and 156
Change from baseline in plasma GL-3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of lyso-GL-3 in plasma was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Change From Baseline in Plasma Glucosylceramide (GL-1) Concentration At Weeks 26, 52, 104, and 156
Change from baseline in plasma GL-1 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GL-1 in plasma was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Change From Baseline in Plasma Monosialodihexosylganglioside (GM3) Concentration At Weeks 26, 52, 104, and 156
Change from baseline in plasma GM3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GM3 in plasma was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Change From Baseline in Urine GL-3 Concentration At Weeks 26, 52, 104, and 156
Change from baseline in urine GL-3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GL-3 in urine was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Change From Baseline in High Sensitivity Cardiac Troponin T At Weeks 26, 52, 104, and 156
Change from baseline in high sensitivity cardiac troponin T was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Change From Baseline in Podocyturia Counts (Per Milligram of Creatinine) At Weeks 12, 26, and 156
Change from baseline in podocyturia was obtained by subtracting baseline value from post-baseline value at Weeks 12, 26, and 156. Urine samples were processed to identify podocyte (podocalyxin, PCX) and parietal cell (claudin 1, CL1) markers. PCX +/CL1 negative cells were identified as podocytes and PCX +/CL1 positive cells as parietal cells with podocyte phenotype. All counts were corrected for urine Cr. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 12, 26, and 156 post-ACT13739 baseline
Summary of Shifts From Baseline in Skin GL-3 Score in Superficial Capillary Endothelial Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score
Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 12, 26, 52, and 156 post-ACT13739 baseline
Summary of Shifts From Baseline in Skin GL-3 Score in Deep Vessels Endothelial Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score
Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 12, 26, 52, and 156 post-ACT13739 baseline
Summary of Shifts From Baseline in Skin GL-3 Score in Deep Vessels Smooth Muscle Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score
Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 12, 26, 52, and 156 post-ACT13739 baseline
Summary of Shifts From Baseline in Skin GL-3 Score in Perineurium Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score
Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 12, 26, 52, and 156 post-ACT13739 baseline
Change From Baseline in Mental Component Summary and Physical Component Summary of the Short Form-36 (SF-36) Health Survey at Weeks 26, 52, 104 and 156
The SF-36 health survey is a participant-reported survey to measure participant's health. It is a 36-item questionnaire used to measure 8 various aspects of health (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health). The score range for each of the 8 aspects was from 0 (maximum disability) to 100 (no disability), higher scores indicating good health condition. Responses on the SF-36 were also used to calculate 2 summary scores: Physical component score (PCS) and mental component score (MCS). The score range for each of these 2 summary scores was from 0 (maximum disability) to 100 (no disability), where higher score indicated less disability or good health condition. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Gastrointestinal (GI) Symptoms: Number of Participants With Abdominal Pain at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the presence of abdominal pain in past 10 days (before each of the specified time points). Participants answered the question: "Do you currently suffer from abdominal (tummy) pain? \[Yes/No\]". For this analysis, baseline was defined as initial ACT13739 study.
Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Gastrointestinal Symptoms: Abdominal Pain Severity Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark the severity of the abdominal pain in past 10 days (before each of the specified time points) on a visual analogue scale (VAS). The scale ranged from 0% (no pain) to 100% (very severe), where higher score indicated more severity. For this analysis, baseline was defined as initial ACT13739 study baseline. Standard deviation (SD) can only be calculated when there are more than 1 participant with data available. Thereby, applicable fields were left blank when SD was not calculable.
Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Gastrointestinal Symptoms: Number of Days With Abdominal Pain Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the number of days they had abdominal pain in past 10 days (before each of the specified time points). Number of days with abdominal pain score was achieved by multiplying number of days with pain \* 10. The score ranges from 10 to 100, where higher score signifies more number of days with pain. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Gastrointestinal Symptoms: Number of Participants With Abdominal Distension at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the presence of abdominal distention in past 10 days (before each of the specified time points). Participants answered the question: "Do you currently suffer from abdominal distension (bloating, swelling or tight tummy)? \[Yes/No\]". For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Gastrointestinal Symptoms: Abdominal Distension Severity Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, and 156
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark the severity of the abdominal distension in past 10 days (before each of the specified time points) on a VAS. The scale ranged from 0% (no distention) to 100% (very severe), where higher score indicated more severity. For this analysis, baseline was defined as initial ACT13739 study baseline. The SD can only be calculated when there are more than 1 participant with data available. Thereby, applicable fields were left blank when SD was not calculable.
Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, and 156 post-ACT13739 baseline
Gastrointestinal Symptoms: Number of Participants in Categories of Response Regarding Eating Less Due to Abdominal Pain/Bloating at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants responded to question "How often do you eat less during meals due to abdominal pain and/or bloating?" in past 10 days (before each of the specified time points) in the categories as 'never', 'occasionally' or 'often'. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Gastrointestinal Symptoms: Satisfaction Over Bowel Habits at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark their satisfaction over bowel habits in past 10 days (before each of the specified time points) on a VAS. The scale ranged from 0% (very happy) to 100% (very unhappy), where higher percentage indicated less satisfaction. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Gastrointestinal Symptoms: Frequency of Bowel Movements - Most Number of Times Bowel Movement Per Day at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the frequency of their bowel movement (per day or per week or per month) in past 10 days (before each of the specified time points) by answering the question "What is the most number of times you move your bowels per day/week/month?". Participants selected their preferred time unit (e.g., per day). Response provided by participants was converted to number of times per day for reporting the results. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Gastrointestinal Symptoms: Frequency of Bowel Movements - Least Number of Times Bowel Movement Per Day at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the frequency of their bowel movement (per day or per week or per month) in past 10 days (before each of the specified time points). Participants answered the question "What is the least number of times you move your bowels per day/week/month?". Participants selected their preferred time unit (e.g., per day). Response provided by participants was converted to number of times per day for reporting the results. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Gastrointestinal Symptoms: Influence of GI Symptoms of Fabry Disease on Life at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark the influence of their GI symptoms of Fabry disease on life in past 10 days (before each of the specified time points) on a VAS. The scale ranged from 0% (no at all) to 100% (completely), where higher percentage indicated more influence of the GI symptoms of the disease on life. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Gastrointestinal Symptoms: Number of Participants With Stool Consistency Assessment by Bristol Stool Scale Scoring at Baseline and Weeks 26, 52, 104, and 156
Participants were asked to rate their stool consistency in past 10 days (before each of the specified time points) on a 7-point Bristol stool scale, according to the following types: 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces. Types 1 and 2 indicate constipation, types 3 and 4 indicate "ideal stools" (easiest to defecate), and 5-7 tending towards diarrhea. Frequency of each stool type was categorized as 'never', occasionally', or 'often'. For this analysis, baseline was defined as the initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Change From Baseline in Beck Depression Inventory (BDI) Total Score at Weeks 26, 104, and 156
The BDI-II Scale was a 21-item scoring tool which measures the existence and severity of symptoms of depression. Each of the 21 items on BDI-II tool represent a depressive symptom. Each symptoms were scored on a 4-point scale of 0 to 3 (0=symptom not present); (3=symptom very intense). Scores for each symptom were added up to obtain the total scores for all 21 items, which were interpreted as follows: Scores of 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression and 29-63: severe depression, where higher scores indicated more depression. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 26, 104, and 156 post-ACT13739 baseline
Change From Baseline in Albumin/Creatinine Ratio (ACR) and Protein/Creatinine Ratio (PCR) at Weeks 26, 52, 104, and 156
For each scheduled visit for this assessment, 3 timed overnight urine samples were collected between 4 to 7 days of each other. All urine samples were collected within a 16-day period. ACR and PCR were determined for each collection. The median of the values determined for the 3 collections/visit was used for analysis. Baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Number of Participants in Categories of Echocardiogram (ECHO) Results at Baseline and at Weeks 26, 52, 104, and 156
The summary statistics of all continuous echocardiogram variables were calculated for each visit. The overall interpretation of the readings were summarized in 3 categories: normal, abnormal but not clinically significant (NCS), and abnormal but clinically significant (CS) categories. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Number of Participants in Categories of Brain Magnetic Resonance Imaging (MRI) Results at Baseline and Weeks 26, and 156
All continuous MRI variables were summarized using descriptive statistics for each visit. The overall interpretation of the readings were summarized in 2 categories as: normal, and abnormal. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 26, and 156 post-ACT13739 baseline
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Weeks 26, 52, 104, and 156
Estimated glomerular filtration rate was used to measure level of kidney function and determine the stage of kidney disease. Change from baseline in eGFR was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104 and 156. For this analysis, baseline was defined as initial ACT13739 study baseline.
Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Chitotriosidase (Chit1) Plasma Concentration Levels at Weeks 52, 104,156 and 160 (End of Treatment Follow-up)
Plasma concentrations of Chit1 over time were determined using mass spectrometry (MS)-based assay. For the analysis, 52 ng/mL was considered as the lower limit of quantification. Although identified in protocol as a secondary endpoint, plasma Chit1 is also an exploratory measure. Only LTS14116 timepoints were analyzed and are presented. Data summarized are the measured values at each time point (not change from baseline). Here, measured value '0.000' denotes no chitotriosidase detected in plasma for the 5 participants at Week 156 reported by laboratory for all evaluable participants.
Time frame: Weeks 52, 104, 156 and 160 (End of Treatment Follow-up) post-ACT13739 baseline
Participants who successfully completed 26 weeks of treatment in prior ACT13739 study (NCT02228460) were eligible to continue their treatment for up to 30 additional months in this extension study LTS14116. Eleven participants had enrolled and were treated in ACT13739 study, and 9 completed study. Of these 9 participants, 8 entered extension study.
| Milestone | GZ/SAR402671 |
|---|---|
| Started | 11 |
| Completed | 9 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 1 |
| Milestone | GZ/SAR402671 |
|---|---|
| Started | 8 |
| Completed | 5 |
| Not completed | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Treatment completed/study not completed | 2 |
Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened during TEAE period (period from the first administration of study drug in ACT13739 through the last administration of the study drug in the combined ACT13739/LTS14116 treatment period plus 1 month or end of study participation for participant, whichever occurred first). For this analysis, baseline was defined as initial ACT13739 study baseline.
| Participants | GZ/SAR402671 |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 9 |
Criteria for potentially clinically significant abnormalities: * Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L); greater than or equal to (\>=)185 g/L; decreased from baseline (DFB) \>=20 g/L * Hematocrit: \<=0.37 volume/volume (v/v); \>=0.55 v/v * Erythrocytes: \>=6 Tera/L * Platelets: lesser than (\<) 100 Giga/L; \>=700 Giga/L * Leukocytes: \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); * Lymphocytes: greater than (\>) 4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L) For this analysis, baseline was defined as initial ACT13739 study baseline.
| Participants | GZ/SAR402671 |
|---|---|
| Hemoglobin <=115 g/L | 1 |
| Hemoglobin >=185 g/L | 0 |
| Hemoglobin DFB >=20 g/L | 0 |
| Hematocrit <=0.37 v/v | 6 |
| Hematocrit >0.55 v/v | 0 |
| Erythrocytes: >=6 Tera/L | 0 |
| Platelets <100 Giga/L | 0 |
| Platelets >=700 Giga/L | 0 |
| Leukocytes <3.0 Giga/L (NB) or <2.0 Giga/L (B) | 0 |
| Leukocytes >=16.0 Giga/L | 0 |
| Neutrophils <1.5 Giga/L (NB) or <1.0 Giga/L (B) | 0 |
| Lymphocytes >4.0 Giga/L | 0 |
| Monocytes >0.7 Giga/L | 2 |
| Basophils >0.1 Giga/L | 1 |
| Eosinophils >0.5 Giga/L or >ULN (ULN >=0.5 Giga/L) | 0 |
Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 millimoles (mmol)/L; \>=160 mmol/L * Potassium: \<3 mmol/L; \>=5.5 mmol/L * Chloride: \<80 mmol/L; \>115 mmol/L.
| Participants | GZ/SAR402671 |
|---|---|
| Sodium <=129 mmol/L | 0 |
| Sodium >=160 mmol/L | 0 |
| Potassium <3 mmol/L | 0 |
| Potassium >=5.5 mmol/L | 0 |
| Chloride <80 mmol/L | 0 |
| Chloride >115 mmol/L | 0 |
Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>3 ULN; \>5 ULN; \>10 ULN and \>20 ULN * Aspartate aminotransferase (AST): \>3 ULN; \>5 ULN; \>10 ULN and \>20 ULN * Alkaline phosphatase: \>1.5 ULN * Bilirubin: \>1.5 ULN; \>2 ULN.
| Participants | GZ/SAR402671 |
|---|---|
| ALT >3 ULN | 0 |
| ALT >5 ULN | 0 |
| ALT >10 ULN | 0 |
| ALT >20 ULN | 0 |
| AST >3 ULN | 0 |
| AST >5 ULN | 0 |
| AST >10 ULN | 0 |
| AST >20 ULN | 0 |
| Alkaline Phosphatase >1.5 ULN | 0 |
| Bilirubin >1.5 ULN | 0 |
| Bilirubin >2 ULN | 0 |
Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \< lower limits of normal (LLN); \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]) * Lipase: \>= 3 ULN * C Reactive Protein (CRP): \> 2 ULN or \> 10 milligrams (mg)/L (if ULN not provided).
| Participants | GZ/SAR402671 |
|---|---|
| Glucose <=3.9 mmol/L and <LLN | 3 |
| Glucose >=11.1 mmol/L (unfas) or >=7 mmol/L (fas) | 1 |
| Albumin <=25 g/L | 0 |
| Lipase >=3 ULN | 0 |
| CRP >2 ULN or >10 mg/L (if ULN not provided) | 2 |
Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromoles per liter (mcmol/L) (Adults); \>=30% change from baseline; \>= 100% change from baseline * Blood urea nitrogen: \>=17 mmol/L * Urate: \<120 mcmol/L; \>408 mcmol/L For this analysis, baseline was defined as initial ACT13739 study baseline.
| Participants | GZ/SAR402671 |
|---|---|
| Creatinine >=150 mcmol/L | 0 |
| Creatinine >=30% change from baseline | 2 |
| Creatinine >=100% change from baseline | 0 |
| Blood Urea Nitrogen >=17 mmol/L | 0 |
| Urate <120 mcmol/L | 0 |
| Urate >408 mcmol/L | 5 |
Criteria with potentially clinically significant urine abnormalities: pH: \<= 4.6; pH: \>= 8.0
| Participants | GZ/SAR402671 |
|---|---|
| pH <= 4.6 | 0 |
| pH >= 8.0 | 0 |
Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure (SBP) supine: \<=95 millimeters of mercury (mmHg) and DFB \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg * Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg * Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm * Weight: \>=5% DFB; \>=5% IFB For this analysis, baseline was defined as initial ACT13739 study baseline.
| Participants | GZ/SAR402671 |
|---|---|
| SBP (supine) <=95 mmHg and DFB >=20 mmHg | 0 |
| SBP (supine) >=160 mmHg and IFB >=20 mmHg | 0 |
| DBP (supine) <=45 mmHg and DFB >=10 mmHg | 0 |
| DBP (supine) >=110 mmHg and IFB >=10 mmHg | 0 |
| HR (supine) <=50 bpm and DFB >= 20 bpm | 1 |
| HR (supine) >=120 bpm and IFB >=20 bpm | 0 |
| Weight >=5% DFB | 3 |
| Weight >=5% IFB | 2 |
Criteria for potentially clinically significant ECG abnormalities: * ECG mean HR: \<30 bpm; \<30 bpm and DFB \>=20 bpm; \<40 bpm; \<40 bpm and DFB \>=20 bpm; \<50 bpm; \<50 bpm and DFB \>=20 bpm; \>90 bpm; \<90 bpm and DFB \>=20 bpm; \>100 bpm; \<100 bpm and DFB \>=20 bpm; \>120 bpm; \<120 bpm and DFB \>=20 bpm * PR Interval: \>200 milliseconds (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25% * QRS duration: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25% * QTc Bazett (QTcB) interval: \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms, IFB \>60 ms * QTc Fridericia (QTc F): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms * QT Interval: \>500 ms For this analysis, baseline was defined as initial ACT13739 study baseline.
| Participants | GZ/SAR402671 |
|---|---|
| ECG Mean HR <30 bpm | 0 |
| ECG Mean HR <30 bpm and DFB >=20 bpm | 0 |
| ECG Mean HR <40 bpm | 0 |
| ECG Mean HR <40 bpm and DFB >=20 bpm | 0 |
| ECG Mean HR <50 bpm | 1 |
| ECG Mean HR <50 bpm and DFB >=20 bpm | 0 |
| ECG Mean HR >90 bpm | 1 |
| ECG Mean HR <90 bpm and DFB >=20 bpm | 0 |
| ECG Mean HR >100 bpm | 0 |
| ECG Mean HR <100 bpm and DFB >=20 bpm | 0 |
| ECG Mean HR >120 bpm | 0 |
| ECG Mean HR <120 bpm and DFB >=20 bpm | 0 |
| PR interval >200 ms | 2 |
| PR interval >200 ms and IFB >=25% | 0 |
| PR interval >220 ms | 0 |
| PR interval >220 ms and IFB >=25% | 0 |
| PR >240 ms | 0 |
| PR interval >240 ms and IFB >=25% | 0 |
| QRS duration >110 ms | 1 |
| QRS duration >110 ms and IFB >=25% | 0 |
| QRS duration >120 ms | 0 |
| QRS duration >120 ms and IFB >=25% | 0 |
| QTcB interval >450 ms | 0 |
| QTcB interval >480 ms | 0 |
| QTc B interval >500 ms | 0 |
| QTcB interval IFB >30 and <=60 ms | 1 |
| QTcB interval IFB >60 ms | 0 |
| QTcF interval >450 ms | 0 |
| QTc F interval >480 ms | 0 |
| QTcF interval >500 ms | 0 |
| QTcF interval IFB >30 and <=60 ms | 0 |
| QTcF interval IFB >60 ms | 0 |
| QT interval >500 ms | 0 |
Change from baseline in plasma GL-3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GL-3 in plasma was determined using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. For this analysis, baseline was defined as initial ACT13739 study baseline.
| micrograms per milliliter (mcg/mL) | GZ/SAR402671 |
|---|---|
| Week 26 | -3.62 ± 1.07 |
| Week 52 | -5.06 ± 1.04 |
| Week 104 | -6.32 ± 2.53 |
| Week 156 | -6.97 ± 2.27 |
Change from baseline in plasma GL-3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of lyso-GL-3 in plasma was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.
| nanograms per mL (ng/mL) | GZ/SAR402671 |
|---|---|
| Week 26 | -30.99 ± 22.83 |
| Week 52 | -37.10 ± 20.69 |
| Week 104 | -39.84 ± 18.12 |
| Week 156 | -48.13 ± 15.65 |
Change from baseline in plasma GL-1 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GL-1 in plasma was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.
| mcg/mL | GZ/SAR402671 |
|---|---|
| Week 26 | -3.26 ± 1.43 |
| Week 52 | -3.58 ± 0.85 |
| Week 104 | -3.70 ± 0.85 |
| Week 156 | -3.23 ± 1.11 |
Change from baseline in plasma GM3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GM3 in plasma was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.
| mcg/mL | GZ/SAR402671 |
|---|---|
| Week 26 | -10.77 ± 6.02 |
| Week 52 | -8.84 ± 4.55 |
| Week 104 | -9.92 ± 3.26 |
| Week 156 | -8.12 ± 5.37 |
Change from baseline in urine GL-3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GL-3 in urine was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.
| mg/mmol creatinine (Cr) | GZ/SAR402671 |
|---|---|
| Week 26 | -0.25 ± 0.19 |
| Week 52 | -0.20 ± 0.22 |
| Week 104 | -0.18 ± 0.22 |
| Week 156 | -0.18 ± 0.27 |
Change from baseline in high sensitivity cardiac troponin T was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. For this analysis, baseline was defined as initial ACT13739 study baseline.
| mcg/L | GZ/SAR402671 |
|---|---|
| Week 26 | 0.0000 ± 0.0000 |
| Week 52 | 0.0105 ± 0.0241 |
| Week 104 | -0.0015 ± 0.0000 |
| Week 156 | 0.0006 ± 0.0027 |
Change from baseline in podocyturia was obtained by subtracting baseline value from post-baseline value at Weeks 12, 26, and 156. Urine samples were processed to identify podocyte (podocalyxin, PCX) and parietal cell (claudin 1, CL1) markers. PCX +/CL1 negative cells were identified as podocytes and PCX +/CL1 positive cells as parietal cells with podocyte phenotype. All counts were corrected for urine Cr. For this analysis, baseline was defined as initial ACT13739 study baseline.
| Count of podocytes/mg Cr | GZ/SAR402671 |
|---|---|
| Week 12 | -1.40 ± 2.69 |
| Week 26 | -1.65 ± 2.97 |
| Week 156 | -2.73 ± 3.97 |
Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.
| Participants | GZ/SAR402671 |
|---|---|
| Baseline Score:1/Week 12 Score:1 | 4 |
| Baseline Score:1/Week 12 Score:2 | 1 |
| Baseline Score:2/Week 12 Score:1 | 3 |
| Baseline Score:2/Week 12 Score:2 | 1 |
| Baseline Score:1/Week 26 Score:1 | 4 |
| Baseline Score:1/Week 26 Score:2 | 1 |
| Baseline Score:2/Week 26 Score:1 | 3 |
| Baseline Score:2/Week 26 Score:2 | 1 |
| Baseline Score:1/Week 52 Score:1 | 3 |
| Baseline Score:2/Week 52 Score:1 | 2 |
| Baseline Score:2/Week 52 Score:2 | 1 |
| Baseline Score:1/Week 156 Score:0 | 2 |
| Baseline Sore:1/Week 156 Score:1 | 1 |
| Baseline Score:2/Week 156 Score:1 | 3 |
Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.
| Participants | GZ/SAR402671 |
|---|---|
| Baseline Score:1/Week 12 Score:2 | 1 |
| Baseline Score:2/Week 12 Score:1 | 2 |
| Baseline Score:2/Week 12 Score:2 | 6 |
| Baseline Score:1/Week 26 Score:1 | 1 |
| Baseline Score:2/Week 26 Score:1 | 2 |
| Baseline Score:2/Week 26 Score:2 | 6 |
| Baseline Score:2/Week 52 Score:1 | 3 |
| Baseline Score:2/Week 52 Score:1.5 | 1 |
| Baseline Sore:2/Week 52 Score:2 | 2 |
| Baseline Score:1/Week 156 Score:1 | 1 |
| Baseline Score:2/Week 156 Score:0.5 | 1 |
| Baseline Score:2/Week 156 Score:1 | 3 |
| Baseline Score:2/Week 156 Score:2 | 1 |
Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.
| Participants | GZ/SAR402671 |
|---|---|
| Baseline Score:1.5/Week 12 Score:2 | 2 |
| Baseline Score:2/Week 12 Score:2 | 7 |
| Baseline Score:1.5/Week 26 Score:1.5 | 2 |
| Baseline Score:2/Week 26 Score:2 | 7 |
| Baseline Score:1.5/Week 52 Score:2 | 1 |
| Baseline Score:2/Week 52 Score:2 | 4 |
| Baseline Score:1.5/Week 156 Score:2 | 1 |
| Baseline Score:2/Week 156 Score:1 | 1 |
| Baseline Score:2/Week 156 Score:1.5 | 1 |
| Baseline Score:2/Week 156 Score:2 | 3 |
Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.
| Participants | GZ/SAR402671 |
|---|---|
| Baseline Score:1/Week 12 Score:2 | 1 |
| Baseline Score:2/Week 12 Score:2 | 8 |
| Baseline Score:1/Week 26 Score:2 | 1 |
| Baseline Score:2/Week 26 Score:2 | 8 |
| Baseline Score:1/Week 52 Score:2 | 1 |
| Baseline Score:2/Week 52 Score:1 | 1 |
| Baseline Score:2/Week 52 Score:1.5 | 1 |
| Baseline Score:2/Week 52 Score:2 | 3 |
| Baseline Score:1/Week 156 Score:1 | 1 |
| Baseline Score:2/Week 156 Score:1.5 | 1 |
| Baseline Score:2/Week 156 Score:2 | 4 |
The SF-36 health survey is a participant-reported survey to measure participant's health. It is a 36-item questionnaire used to measure 8 various aspects of health (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health). The score range for each of the 8 aspects was from 0 (maximum disability) to 100 (no disability), higher scores indicating good health condition. Responses on the SF-36 were also used to calculate 2 summary scores: Physical component score (PCS) and mental component score (MCS). The score range for each of these 2 summary scores was from 0 (maximum disability) to 100 (no disability), where higher score indicated less disability or good health condition. For this analysis, baseline was defined as initial ACT13739 study baseline.
| units on a scale | GZ/SAR402671 |
|---|---|
| Physical Component Summary: Week 26 | 8.39 ± 6.88 |
| Physical Component Summary: Week 52 | 7.70 ± 7.76 |
| Physical Component Summary: Week 104 | 9.72 ± 9.02 |
| Physical Component Summary: Week 156 | 5.30 ± 11.83 |
| Mental Component Summary: Week 26 | -3.31 ± 20.34 |
| Mental Component Summary: Week 52 | 1.69 ± 8.27 |
| Mental Component Summary: Week 104 | 6.48 ± 8.14 |
| Mental Component Summary: Week 156 | 2.87 ± 14.17 |
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the presence of abdominal pain in past 10 days (before each of the specified time points). Participants answered the question: "Do you currently suffer from abdominal (tummy) pain? \[Yes/No\]". For this analysis, baseline was defined as initial ACT13739 study.
| Participants | GZ/SAR402671 |
|---|---|
| Baseline — No | 5 |
| Baseline — Yes | 6 |
| Week 2 — No | 6 |
| Week 2 — Yes | 5 |
| Week 4 — No | 7 |
| Week 4 — Yes | 4 |
| Week 8 — No | 8 |
| Week 8 — Yes | 3 |
| Week 12 — No | 8 |
| Week 12 — Yes | 2 |
| Week 18 — No | 7 |
| Week 18 — Yes | 2 |
| Week 26 — No | 6 |
| Week 26 — Yes | 3 |
| Week 52 — No | 5 |
| Week 52 — Yes | 2 |
| Week 104 — No | 5 |
| Week 104 — Yes | 2 |
| Week 156 — No | 5 |
| Week 156 — Yes | 2 |
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark the severity of the abdominal pain in past 10 days (before each of the specified time points) on a visual analogue scale (VAS). The scale ranged from 0% (no pain) to 100% (very severe), where higher score indicated more severity. For this analysis, baseline was defined as initial ACT13739 study baseline. Standard deviation (SD) can only be calculated when there are more than 1 participant with data available. Thereby, applicable fields were left blank when SD was not calculable.
| score on a 0-100 percent scale | GZ/SAR402671 |
|---|---|
| Baseline | 52.50 ± 20.50 |
| Week 2 | 35.60 ± 18.47 |
| Week 4 | 29.75 ± 20.07 |
| Week 8 | 29.00 ± 21.28 |
| Week 12 | 40.00 ± 21.21 |
| Week 18 | 43.00 ± 29.70 |
| Week 26 | 31.33 ± 32.81 |
| Week 52 | 21.00 |
| Week 104 | 21.00 |
| Week 156 | 15.00 ± 7.07 |
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the number of days they had abdominal pain in past 10 days (before each of the specified time points). Number of days with abdominal pain score was achieved by multiplying number of days with pain \* 10. The score ranges from 10 to 100, where higher score signifies more number of days with pain. For this analysis, baseline was defined as initial ACT13739 study baseline.
| score on a scale | GZ/SAR402671 |
|---|---|
| Baseline | 38.33 ± 31.89 |
| Week 2 | 26.00 ± 20.74 |
| Week 4 | 25.00 ± 20.82 |
| Week 8 | 25.00 ± 23.80 |
| Week 12 | 35.00 ± 7.07 |
| Week 18 | 35.00 ± 21.21 |
| Week 26 | 30.00 ± 34.64 |
| Week 52 | 7.00 ± 12.12 |
| Week 104 | 5.00 ± 7.07 |
| Week 156 | 20.00 ± 0.00 |
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the presence of abdominal distention in past 10 days (before each of the specified time points). Participants answered the question: "Do you currently suffer from abdominal distension (bloating, swelling or tight tummy)? \[Yes/No\]". For this analysis, baseline was defined as initial ACT13739 study baseline.
| Participants | GZ/SAR402671 |
|---|---|
| Baseline — No | 9 |
| Baseline — Yes | 2 |
| Week 2 — No | 8 |
| Week 2 — Yes | 3 |
| Week 4 — No | 7 |
| Week 4 — Yes | 4 |
| Week 8 — No | 9 |
| Week 8 — Yes | 2 |
| Week 12 — No | 9 |
| Week 12 — Yes | 1 |
| Week 18 — No | 8 |
| Week 18 — Yes | 1 |
| Week 26 — No | 8 |
| Week 26 — Yes | 1 |
| Week 52 — No | 7 |
| Week 52 — Yes | 0 |
| Week 104 — No | 7 |
| Week 104 — Yes | 0 |
| Week 156 — No | 6 |
| Week 156 — Yes | 1 |
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark the severity of the abdominal distension in past 10 days (before each of the specified time points) on a VAS. The scale ranged from 0% (no distention) to 100% (very severe), where higher score indicated more severity. For this analysis, baseline was defined as initial ACT13739 study baseline. The SD can only be calculated when there are more than 1 participant with data available. Thereby, applicable fields were left blank when SD was not calculable.
| score on a 0-100 percent scale | GZ/SAR402671 |
|---|---|
| Baseline | 45.33 ± 24.01 |
| Week 2 | 38.67 ± 38.42 |
| Week 4 | 21.00 ± 26.15 |
| Week 8 | 35.00 ± 48.08 |
| Week 12 | 72.00 |
| Week 18 | 69.00 |
| Week 26 | 80.00 |
| Week 156 | 5.00 |
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants responded to question "How often do you eat less during meals due to abdominal pain and/or bloating?" in past 10 days (before each of the specified time points) in the categories as 'never', 'occasionally' or 'often'. For this analysis, baseline was defined as initial ACT13739 study baseline.
| Participants | GZ/SAR402671 |
|---|---|
| Baseline — Never | 4 |
| Baseline — Occasionally | 5 |
| Baseline — Often | 2 |
| Week 2 — Never | 6 |
| Week 2 — Occasionally | 3 |
| Week 2 — Often | 2 |
| Week 4 — Never | 6 |
| Week 4 — Occasionally | 3 |
| Week 4 — Often | 2 |
| Week 8 — Never | 7 |
| Week 8 — Occasionally | 3 |
| Week 8 — Often | 1 |
| Week 12 — Never | 5 |
| Week 12 — Occasionally | 3 |
| Week 12 — Often | 2 |
| Week 18 — Never | 4 |
| Week 18 — Occasionally | 3 |
| Week 18 — Often | 2 |
| Week 26 — Never | 4 |
| Week 26 — Occasionally | 3 |
| Week 26 — Often | 2 |
| Week 52 — Never | 3 |
| Week 52 — Occasionally | 3 |
| Week 52 — Often | 1 |
| Week 104 — Never | 4 |
| Week 104 — Occasionally | 3 |
| Week 104 — Often | 0 |
| Week 156 — Never | 4 |
| Week 156 — Occasionally | 3 |
| Week 156 — Often | 0 |
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark their satisfaction over bowel habits in past 10 days (before each of the specified time points) on a VAS. The scale ranged from 0% (very happy) to 100% (very unhappy), where higher percentage indicated less satisfaction. For this analysis, baseline was defined as initial ACT13739 study baseline.
| score on a 0-100 percent scale | GZ/SAR402671 |
|---|---|
| Baseline | 26.55 ± 19.09 |
| Week 2 | 30.82 ± 21.17 |
| Week 4 | 36.09 ± 28.68 |
| Week 8 | 34.27 ± 27.02 |
| Week 12 | 21.50 ± 17.83 |
| Week 18 | 23.89 ± 21.29 |
| Week 26 | 35.56 ± 29.37 |
| Week 52 | 19.00 ± 17.05 |
| Week 104 | 18.00 ± 15.18 |
| Week 156 | 34.02 ± 36.67 |
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the frequency of their bowel movement (per day or per week or per month) in past 10 days (before each of the specified time points) by answering the question "What is the most number of times you move your bowels per day/week/month?". Participants selected their preferred time unit (e.g., per day). Response provided by participants was converted to number of times per day for reporting the results. For this analysis, baseline was defined as initial ACT13739 study baseline.
| number of bowel movements per day | GZ/SAR402671 |
|---|---|
| Baseline | 2.36 ± 1.03 |
| Week 2 | 2.00 ± 0.63 |
| Week 4 | 2.00 ± 1.00 |
| Week 8 | 1.74 ± 1.07 |
| Week 12 | 2.04 ± 1.08 |
| Week 18 | 2.17 ± 1.05 |
| Week 26 | 2.16 ± 1.07 |
| Week 52 | 2.08 ± 1.00 |
| Week 104 | 1.96 ± 1.05 |
| Week 156 | 1.65 ± 0.61 |
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the frequency of their bowel movement (per day or per week or per month) in past 10 days (before each of the specified time points). Participants answered the question "What is the least number of times you move your bowels per day/week/month?". Participants selected their preferred time unit (e.g., per day). Response provided by participants was converted to number of times per day for reporting the results. For this analysis, baseline was defined as initial ACT13739 study baseline.
| number of bowel movements per day | GZ/SAR402671 |
|---|---|
| Baseline | 0.78 ± 0.56 |
| Week 2 | 0.66 ± 0.43 |
| Week 4 | 0.65 ± 0.62 |
| Week 8 | 0.62 ± 0.64 |
| Week 12 | 0.67 ± 0.65 |
| Week 18 | 0.73 ± 0.65 |
| Week 26 | 0.75 ± 0.40 |
| Week 52 | 0.76 ± 0.72 |
| Week 104 | 0.61 ± 0.49 |
| Week 156 | 0.92 ± 0.62 |
Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark the influence of their GI symptoms of Fabry disease on life in past 10 days (before each of the specified time points) on a VAS. The scale ranged from 0% (no at all) to 100% (completely), where higher percentage indicated more influence of the GI symptoms of the disease on life. For this analysis, baseline was defined as initial ACT13739 study baseline.
| score on a 0-100 percent scale | GZ/SAR402671 |
|---|---|
| Baseline | 34.36 ± 26.47 |
| Week 2 | 26.73 ± 25.22 |
| Week 4 | 21.27 ± 19.88 |
| Week 8 | 22.09 ± 19.77 |
| Week 12 | 17.50 ± 19.92 |
| Week 18 | 24.89 ± 23.34 |
| Week 26 | 36.44 ± 30.18 |
| Week 52 | 20.33 ± 22.04 |
| Week 104 | 26.50 ± 23.31 |
| Week 156 | 19.82 ± 21.14 |
Participants were asked to rate their stool consistency in past 10 days (before each of the specified time points) on a 7-point Bristol stool scale, according to the following types: 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces. Types 1 and 2 indicate constipation, types 3 and 4 indicate "ideal stools" (easiest to defecate), and 5-7 tending towards diarrhea. Frequency of each stool type was categorized as 'never', occasionally', or 'often'. For this analysis, baseline was defined as the initial ACT13739 study baseline.
| Participants | GZ/SAR402671 |
|---|---|
| Stool Type 1: Baseline — Never | 11 |
| Stool Type 1: Baseline — Occasionally | 0 |
| Stool Type 1: Baseline — Often | 0 |
| Stool Type 1: Week 26 — Never | 8 |
| Stool Type 1: Week 26 — Occasionally | 1 |
| Stool Type 1: Week 26 — Often | 0 |
| Stool Type 1: Week 52 — Never | 6 |
| Stool Type 1: Week 52 — Occasionally | 0 |
| Stool Type 1: Week 52 — Often | 1 |
| Stool Type 1: Week 104 — Never | 6 |
| Stool Type 1: Week 104 — Occasionally | 0 |
| Stool Type 1: Week 104 — Often | 1 |
| Stool Type 1: Week 156 — Never | 5 |
| Stool Type 1: Week 156 — Occasionally | 1 |
| Stool Type 1: Week 156 — Often | 1 |
| Stool Type 2: Baseline — Never | 6 |
| Stool Type 2: Baseline — Occasionally | 5 |
| Stool Type 2: Baseline — Often | 0 |
| Stool Type 2: Week 26 — Never | 6 |
| Stool Type 2: Week 26 — Occasionally | 0 |
| Stool Type 2: Week 26 — Often | 3 |
| Stool Type 2: Week 52 — Never | 3 |
| Stool Type 2: Week 52 — Occasionally | 4 |
| Stool Type 2: Week 52 — Often | 0 |
| Stool Type 2: Week 104 — Never | 4 |
| Stool Type 2: Week 104 — Occasionally | 2 |
| Stool Type 2: Week 104 — Often | 1 |
| Stool Type 2: Week 156 — Never | 2 |
| Stool Type 2: Week 156 — Occasionally | 3 |
| Stool Type 2: Week 156 — Often | 2 |
| Stool Type 3: Baseline — Never | 1 |
| Stool Type 3: Baseline — Occasionally | 4 |
| Stool Type 3: Baseline — Often | 6 |
| Stool Type 3: Week 26 — Never | 1 |
| Stool Type 3: Week 26 — Occasionally | 3 |
| Stool Type 3: Week 26 — Often | 5 |
| Stool Type 3: Week 52 — Never | 0 |
| Stool Type 3: Week 52 — Occasionally | 3 |
| Stool Type 3: Week 52 — Often | 4 |
| Stool Type 3: Week 104 — Never | 0 |
| Stool Type 3: Week 104 — Occasionally | 6 |
| Stool Type 3: Week 104 — Often | 1 |
| Stool Type 3: Week 156 — Never | 0 |
| Stool Type 3: Week 156 — Occasionally | 4 |
| Stool Type 3: Week 156 — Often | 3 |
| Stool Type 4: Baseline — Never | 1 |
| Stool Type 4: Baseline — Occasionally | 8 |
| Stool Type 4: Baseline — Often | 2 |
| Stool Type 4: Week 26 — Never | 2 |
| Stool Type 4: Week 26 — Occasionally | 4 |
| Stool Type 4: Week 26 — Often | 3 |
| Stool Type 4: Week 52 — Never | 3 |
| Stool Type 4: Week 52 — Occasionally | 1 |
| Stool Type 4: Week 52 — Often | 3 |
| Stool Type 4: Week 104 — Never | 2 |
| Stool Type 4: Week 104 — Occasionally | 3 |
| Stool Type 4: Week 104 — Often | 2 |
| Stool Type 4: Week 156 — Never | 3 |
| Stool Type 4: Week 156 — Occasionally | 2 |
| Stool Type 4: Week 156 — Often | 2 |
| Stool type 5: Baseline — Never | 1 |
| Stool type 5: Baseline — Occasionally | 9 |
| Stool type 5: Baseline — Often | 1 |
| Stool type 5: Week 26 — Never | 4 |
| Stool type 5: Week 26 — Occasionally | 4 |
| Stool type 5: Week 26 — Often | 1 |
| Stool type 5: Week 52 — Never | 5 |
| Stool type 5: Week 52 — Occasionally | 2 |
| Stool type 5: Week 52 — Often | 0 |
| Stool type 5: Week 104 — Never | 4 |
| Stool type 5: Week 104 — Occasionally | 1 |
| Stool type 5: Week 104 — Often | 2 |
| Stool type 5: Week 156 — Never | 3 |
| Stool type 5: Week 156 — Occasionally | 3 |
| Stool type 5: Week 156 — Often | 1 |
| Stool Type 6: Baseline — Never | 5 |
| Stool Type 6: Baseline — Occasionally | 5 |
| Stool Type 6: Baseline — Often | 1 |
| Stool Type 6: Week 26 — Never | 4 |
| Stool Type 6: Week 26 — Occasionally | 4 |
| Stool Type 6: Week 26 — Often | 1 |
| Stool Type 6: Week 52 — Never | 4 |
| Stool Type 6: Week 52 — Occasionally | 2 |
| Stool Type 6: Week 52 — Often | 1 |
| Stool Type 6: Week 104 — Never | 3 |
| Stool Type 6: Week 104 — Occasionally | 3 |
| Stool Type 6: Week 104 — Often | 1 |
| Stool Type 6: Week 156 — Never | 4 |
| Stool Type 6: Week 156 — Occasionally | 3 |
| Stool Type 6: Week 156 — Often | 0 |
| Stool Type 7: Baseline — Never | 5 |
| Stool Type 7: Baseline — Occasionally | 5 |
| Stool Type 7: Baseline — Often | 1 |
| Stool Type 7: Week 26 — Never | 5 |
| Stool Type 7: Week 26 — Occasionally | 4 |
| Stool Type 7: Week 26 — Often | 0 |
| Stool Type 7: Week 52 — Never | 5 |
| Stool Type 7: Week 52 — Occasionally | 2 |
| Stool Type 7: Week 52 — Often | 0 |
| Stool Type 7: Week 104 — Never | 4 |
| Stool Type 7: Week 104 — Occasionally | 3 |
| Stool Type 7: Week 104 — Often | 0 |
| Stool Type 7: Week 156 — Never | 3 |
| Stool Type 7: Week 156 — Occasionally | 3 |
| Stool Type 7: Week 156 — Often | 1 |
The BDI-II Scale was a 21-item scoring tool which measures the existence and severity of symptoms of depression. Each of the 21 items on BDI-II tool represent a depressive symptom. Each symptoms were scored on a 4-point scale of 0 to 3 (0=symptom not present); (3=symptom very intense). Scores for each symptom were added up to obtain the total scores for all 21 items, which were interpreted as follows: Scores of 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression and 29-63: severe depression, where higher scores indicated more depression. For this analysis, baseline was defined as initial ACT13739 study baseline.
| score on a scale | GZ/SAR402671 |
|---|---|
| Week 26 | -0.89 ± 8.13 |
| Week 104 | 2.00 ± 3.37 |
| Week 156 | -3.43 ± 7.09 |
For each scheduled visit for this assessment, 3 timed overnight urine samples were collected between 4 to 7 days of each other. All urine samples were collected within a 16-day period. ACR and PCR were determined for each collection. The median of the values determined for the 3 collections/visit was used for analysis. Baseline was defined as initial ACT13739 study baseline.
| mg/g | GZ/SAR402671 |
|---|---|
| ACR: Week 26 | -26.22 ± 26.75 |
| ACR: Week 52 | 1.00 ± 57.23 |
| ACR: Week 104 | 12.21 ± 71.82 |
| ACR: Week 156 | -1.14 ± 54.80 |
| PCR: Week 26 | -38.33 ± 24.40 |
| PCR: Week 52 | 0.33 ± 62.11 |
| PCR: Week 104 | -12.88 ± 76.97 |
| PCR: Week 156 | -34.38 ± 71.40 |
The summary statistics of all continuous echocardiogram variables were calculated for each visit. The overall interpretation of the readings were summarized in 3 categories: normal, abnormal but not clinically significant (NCS), and abnormal but clinically significant (CS) categories. For this analysis, baseline was defined as initial ACT13739 study baseline.
| Participants | GZ/SAR402671 |
|---|---|
| Baseline — Normal | 6 |
| Baseline — Abnormal NCS | 2 |
| Baseline — Abnormal CS | 0 |
| Week 26 — Normal | 6 |
| Week 26 — Abnormal NCS | 3 |
| Week 26 — Abnormal CS | 0 |
| Week 52 — Normal | 5 |
| Week 52 — Abnormal NCS | 2 |
| Week 52 — Abnormal CS | 0 |
| Week 104 — Normal | 4 |
| Week 104 — Abnormal NCS | 3 |
| Week 104 — Abnormal CS | 0 |
| Week 156 — Normal | 5 |
| Week 156 — Abnormal NCS | 2 |
| Week 156 — Abnormal CS | 0 |
All continuous MRI variables were summarized using descriptive statistics for each visit. The overall interpretation of the readings were summarized in 2 categories as: normal, and abnormal. For this analysis, baseline was defined as initial ACT13739 study baseline.
| Participants | GZ/SAR402671 |
|---|---|
| Baseline — Normal | 6 |
| Baseline — Abnormal | 4 |
| Week 26 — Normal | 7 |
| Week 26 — Abnormal | 2 |
| Week 156 — Normal | 4 |
| Week 156 — Abnormal | 3 |
Estimated glomerular filtration rate was used to measure level of kidney function and determine the stage of kidney disease. Change from baseline in eGFR was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104 and 156. For this analysis, baseline was defined as initial ACT13739 study baseline.
| mL/min/1.73m^2 | GZ/SAR402671 |
|---|---|
| Week 26 | -3.43 ± 8.64 |
| Week 52 | -5.57 ± 11.07 |
| Week 104 | -5.71 ± 10.23 |
| Week 156 | -4.83 ± 17.54 |
Plasma concentrations of Chit1 over time were determined using mass spectrometry (MS)-based assay. For the analysis, 52 ng/mL was considered as the lower limit of quantification. Although identified in protocol as a secondary endpoint, plasma Chit1 is also an exploratory measure. Only LTS14116 timepoints were analyzed and are presented. Data summarized are the measured values at each time point (not change from baseline). Here, measured value '0.000' denotes no chitotriosidase detected in plasma for the 5 participants at Week 156 reported by laboratory for all evaluable participants.
| ng/mL | GZ/SAR402671 |
|---|---|
| Week 52 | 35.965 ± 46.520 |
| Week 104 | 12.785 ± 20.993 |
| Week 156 | 0.000 ± 0.000 |
| Week 160 (End of Treatment Follow-up) | 6.483 ± 6.309 |
Collected over From baseline of ACT13739 study up to 37 months post-ACT13739 baseline.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GZ/SAR402671 | 0/11 (0%) | 3/11 (27.3%) | 9/11 (81.8%) |
| Event | GZ/SAR402671 |
|---|---|
| HaemolysisBlood and lymphatic system disorders | 1/11 |
| Deafness unilateralEar and labyrinth disorders | 1/11 |
| VertigoEar and labyrinth disorders | 1/11 |
| Floppy infantMusculoskeletal and connective tissue disorders | 1/11 |
| Ischaemic strokeNervous system disorders | 1/11 |
| Depressed moodPsychiatric disorders | 1/11 |
| Intentional self-injuryPsychiatric disorders | 1/11 |
| Event | GZ/SAR402671 |
|---|---|
| NasopharyngitisInfections and infestations | 4/11 |
| HeadacheNervous system disorders | 4/11 |
| TinnitusEar and labyrinth disorders | 3/11 |
| Upper respiratory tract infectionInfections and infestations | 3/11 |
| AngiokeratomaSkin and subcutaneous tissue disorders | 3/11 |
| CardiomyopathyCardiac disorders | 2/11 |
| Retinal vascular disorderEye disorders | 2/11 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 2/11 |
| NauseaGastrointestinal disorders | 2/11 |
| VomitingGastrointestinal disorders | 2/11 |
Analysis performed on all participants who were initially enrolled in the ACT13739 study.
| Age, Continuous(years) | GZ/SAR402671 |
|---|---|
| Mean | 26.5 ± 7.6 |
| Sex: Female, Male(Participants) | GZ/SAR402671 |
|---|---|
| Female | 0 |
| Male | 11 |
| Race/Ethnicity, Customized(Participants) | GZ/SAR402671 |
|---|---|
| Race — Caucasian/White | 8 |
| Race — Other | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2015 to primary completion in Nov 2018, 40 months.
Results were first posted in Dec 2019, 1 year after primary completion.
Of 11 phase 2 interventional studies under Fabry Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 24. This study's 40 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Venglustat